Correlation Between Halozyme Therapeutics and Vaxcyte
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Vaxcyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Vaxcyte into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Vaxcyte, you can compare the effects of market volatilities on Halozyme Therapeutics and Vaxcyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Vaxcyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Vaxcyte.
Diversification Opportunities for Halozyme Therapeutics and Vaxcyte
0.5 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Halozyme and Vaxcyte is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Vaxcyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vaxcyte and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Vaxcyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vaxcyte has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Vaxcyte go up and down completely randomly.
Pair Corralation between Halozyme Therapeutics and Vaxcyte
Given the investment horizon of 90 days Halozyme Therapeutics is expected to generate 1.44 times less return on investment than Vaxcyte. But when comparing it to its historical volatility, Halozyme Therapeutics is 3.74 times less risky than Vaxcyte. It trades about 0.34 of its potential returns per unit of risk. Vaxcyte is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest 8,106 in Vaxcyte on November 9, 2024 and sell it today you would earn a total of 796.00 from holding Vaxcyte or generate 9.82% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Halozyme Therapeutics vs. Vaxcyte
Performance |
| Timeline |
| Halozyme Therapeutics |
| Vaxcyte |
Halozyme Therapeutics and Vaxcyte Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Halozyme Therapeutics and Vaxcyte
The main advantage of trading using opposite Halozyme Therapeutics and Vaxcyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Vaxcyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vaxcyte will offset losses from the drop in Vaxcyte's long position.| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
| Vaxcyte vs. Larimar Therapeutics | Vaxcyte vs. Syndax Pharmaceuticals | Vaxcyte vs. Merus BV | Vaxcyte vs. Sutro Biopharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |